Generali Asset Management SPA SGR cut its stake in Aflac Incorporated (NYSE:AFL - Free Report) by 5.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,040 shares of the financial services provider's stock after selling 2,890 shares during the quarter. Generali Asset Management SPA SGR's holdings in Aflac were worth $5,066,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. AlphaCore Capital LLC purchased a new position in shares of Aflac in the first quarter valued at $28,000. Hilltop National Bank purchased a new position in Aflac during the second quarter worth about $32,000. Golden State Wealth Management LLC grew its position in Aflac by 121.9% during the first quarter. Golden State Wealth Management LLC now owns 304 shares of the financial services provider's stock worth $34,000 after buying an additional 167 shares in the last quarter. Groupe la Francaise purchased a new position in Aflac during the first quarter worth about $34,000. Finally, Garde Capital Inc. purchased a new position in Aflac during the first quarter worth about $36,000. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Aflac
In other news, Director Joseph L. Moskowitz sold 1,000 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $102.57, for a total value of $102,570.00. Following the completion of the sale, the director owned 25,105 shares of the company's stock, valued at approximately $2,575,019.85. The trade was a 3.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.90% of the company's stock.
Aflac Trading Down 1.5%
Shares of AFL stock opened at $109.80 on Thursday. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average price of $108.18 and a two-hundred day moving average price of $105.52. Aflac Incorporated has a 12-month low of $96.95 and a 12-month high of $115.44. The firm has a market cap of $58.73 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 3.09 and a beta of 0.86.
Aflac (NYSE:AFL - Get Free Report) last released its earnings results on Monday, February 27th. The financial services provider reported $1.07 earnings per share for the quarter. Aflac had a return on equity of 15.08% and a net margin of 15.32%.The company had revenue of $5.91 billion during the quarter. Equities analysts anticipate that Aflac Incorporated will post 6.88 EPS for the current fiscal year.
Aflac announced that its board has authorized a share repurchase plan on Tuesday, August 12th that authorizes the company to repurchase 100,000,000 shares. This repurchase authorization authorizes the financial services provider to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.
Aflac Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Wednesday, August 20th were paid a $0.58 dividend. This represents a $2.32 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Wednesday, August 20th. Aflac's payout ratio is 52.61%.
Analysts Set New Price Targets
Several equities analysts recently commented on the company. JPMorgan Chase & Co. boosted their target price on Aflac from $96.00 to $100.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded Aflac from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Piper Sandler set a $125.00 target price on Aflac and gave the stock an "overweight" rating in a research report on Tuesday, October 7th. Evercore ISI set a $110.00 price target on Aflac and gave the stock an "underperform" rating in a research note on Thursday, October 9th. Finally, UBS Group dropped their price target on Aflac from $114.00 to $111.00 and set a "neutral" rating for the company in a research note on Wednesday, August 6th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $109.45.
View Our Latest Stock Analysis on Aflac
Aflac Profile
(
Free Report)
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aflac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aflac wasn't on the list.
While Aflac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.